Table 2.
Summary of HIV TDR at both ANCs and IDCCs in Botswana
| NRTIs | NNRTIs | PIs | Samples with resistance, % (n) | Resistance to first-line therapya, % (n) | |
|---|---|---|---|---|---|
| ANCs | |||||
| Gaborone | |||||
| 2012 (n = 105) | — | K101E, G190A | L90M | 2.9 (3) | 1.0 (1)b |
| 2014–15 (n = 62) | — | K103N (4), G190A | L90M | 9.7 (6) | 8.1 (5)b |
| Molepolole (n = 34) | — | — | — | — | — |
| Mochudi (n = 33) | M184Vc | K103N, Y181Cc | M46I | 9.1 (3) | 6.1 (2) |
| total (n = 234) | 5.1 (12) | 3.4 (8) | |||
| IDCCs | |||||
| Gaborone (n = 115) | T215S | K101E | M46I, V82L | 3.5 (4) | — |
| Molepolole (n = 49) | — | — | — | — | — |
| Mochudi (n = 24) | — | — | — | — | — |
| total (n = 188) | 2.1 (4) | — | |||
aResistance to first-line therapy is defined as a mutation that confers intermediate- or high-level resistance to emtricitabine/tenofovir disoproxil fumarate/efavirenz.
bP = 0.027 by Fisher's exact test for differences in resistance at ANCs in Gaborone in 2012 and 2014–15.
cSame individual.